免疫治疗联合经动脉放射性栓塞治疗晚期肝细胞癌
基于美国国家癌症数据库2017年1月1日至2019年12月31日诊断的1664例晚期肝细胞癌患者,比较一线联合免疫治疗与经动脉放射性栓塞(TARE)与单用免疫治疗的疗效。联合组142例,单用免疫治疗组1522例,联合组中位总生存期显著更高(19.8 vs 9.5个月),多因素分析调整后死亡风险降低(调整HR 0.50,95%CI 0.36-0.68,P<0.001)。
要点
- 晚期肝细胞癌联合TARE与免疫治疗组中位总生存期19.8个月,单用免疫治疗组9.5个月。
- 联合治疗独立关联死亡风险降低(调整HR 0.50,95%CI 0.36-0.68,P<0.001)。
- 结果在亚组及倾向性评分匹配和逆概率治疗加权敏感性分析中一致。
核心结论
- 在晚期肝细胞癌患者中,TARE联合免疫治疗与单用免疫治疗相比与生存改善相关。
- 作者认为该发现凸显了在这些患者中开展评估联合治疗的大型临床试验的重要性。
研究设计与样本
- 使用美国国家癌症数据库识别2017年1月1日至2019年12月31日诊断的晚期肝细胞癌患者。
- 纳入接受联合治疗或单用免疫治疗作为一线治疗的患者,共1664例,其中联合TARE/免疫治疗142例,单用免疫治疗1522例。
主要发现
- 联合治疗组中位总生存期显著高于单用免疫治疗组(19.8 vs 9.5个月)。
- 多因素分析中联合治疗独立关联死亡风险降低(调整HR 0.50,95%CI 0.36-0.68,P<0.001)。
- 接受联合治疗与在学术中心接受诊疗相关,与种族/族裔少数地位(西班牙裔和黑人个体)呈负相关。
- 结果在各亚组以及使用倾向性评分匹配和逆概率治疗加权的敏感性分析中一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The efficacy and safety of combined immunotherapy and transarterial radioembolization (TARE) were suggested in preclinical and early-phase trials, but these were limited by small sample sizes. We sought to compare the efficacy of combined therapy and immunotherapy alone in patients with advanced hepatocellular carcinoma (HCC). METHODS: The National Cancer Database was used to identify patients with advanced HCC diagnosed between January 1, 2017, and December 31, 2019. We included patients who received combined therapy or immunotherapy alone as first-line treatment. Multivariable logistic regression was conducted to determine predictors of combined therapy. Kaplan-Meier and Cox regression approaches were used to identify predictors of overall survival and to compare hazards of mortality between the patients who received combined therapy and immunotherapy alone. RESULTS: Of 1,664 eligible patients with advanced-stage HCC, 142 received combined TARE/immunotherapy and 1,522 received immunotherapy alone. Receipt of combination therapy was associated with care at an academic center and inversely associated with racial/ethnic minority status (Hispanic and Black individuals). The median overall survival was significantly higher in the combination group than in the immunotherapy alone group (19.8 vs 9.5 months). In multivariable analysis, combined therapy was independently associated with reduced mortality (adjusted hazard ratio 0.50, 95% confidence interval: 0.36-0.68, P < 0.001). Results were consistent across subgroups and in sensitivity analyses using propensity score matching and inverse probability of treatment weighting. DISCUSSION: The combination of TARE and immunotherapy was associated with improved survival compared with immunotherapy alone in patients with advanced-stage HCC. Our findings underly the importance of large clinical trials evaluating combination therapy in these patients.
引用
- Yeo YH, Liang J, Lauzon M, et al. Immunotherapy and Transarterial Radioembolization Combination Treatment for Advanced Hepatocellular Carcinoma. Am J Gastroenterol. 2023. PMID: 37561061. doi:10.14309/ajg.0000000000002467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。